FDA Symlin Reviewer Cautions Against Diabetes Claims For Anorexic Agents
Executive Summary
FDA should be wary of approving a diabetes claim for a drug whose mechanism of action is reducing body weight, FDA reviewer Robert Misbin, MD, said in briefing materials prepared for the advisory committee review of Amylin's Symlin.